FINNENCE ▪ THE WIRE FILE
THE WIRE · № 79776
Company■ Mixed
New Phase 3 trial: A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis — Almirall, S.A.
KINDCompany
DIRECTION■ Mixed
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
New Phase 3 trial for lebrikizumab expands atopic dermatitis indications, signaling pipeline commitment.
Lebrikizumab indication expansion underway
CATALYST TO WATCH
Enrollment and interim data
MAIN RISK
Trial not yet recruiting, years from data
FULL DISPATCH
Sponsor: Almirall, S.A.; Status: Not Yet Recruiting; Conditions: Atopic Dermatitis; Interventions: Lebrikizumab, Placebo, Lebrikizumab; Enrollment: 230 (estimated); First posted: 2026-10-14; NCT: NCT07873801
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
AFFECTEDSPDR Biotech ETF · XBI
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare, XBI
Phase 3 results posted: A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome — Hoffmann-La Roche2026-10-14 12:00 UTC
Phase 3 results posted: A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome — Hoffmann-La Roche2026-10-14 12:00 UTC
→CORRELATIONshares Healthcare, XBI
Phase 3 results posted: A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa) — Ultragenyx Pharmaceutical Inc2026-10-14 12:00 UTC
Phase 3 results posted: A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa) — Ultragenyx Pharmaceutical Inc2026-10-14 12:00 UTC
→CORRELATIONshares Healthcare
WIN Expands Executive Leadership Team Following Period of Rapid Growth2026-10-14 12:57 UTC
WIN Expands Executive Leadership Team Following Period of Rapid Growth2026-10-14 12:57 UTC
→CORRELATIONshares Healthcare
FLSC IPO News - Biotech-focused SPAC Frazier Life Sciences Acquisition II prices $75 million IPO2026-10-14 12:32 UTC
FLSC IPO News - Biotech-focused SPAC Frazier Life Sciences Acquisition II prices $75 million IPO2026-10-14 12:32 UTC
→CORRELATIONshares Healthcare
Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs2026-10-14 13:15 UTC
Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs2026-10-14 13:15 UTC
→CORRELATIONshares Healthcare
Attorney Tracy Paulsen Brings Focused Experience to Growing GLP-1 Vision Loss and NAION Litigation2026-10-14 13:17 UTC
Attorney Tracy Paulsen Brings Focused Experience to Growing GLP-1 Vision Loss and NAION Litigation2026-10-14 13:17 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.